抗抑郁药对心血管代谢及其他生理参数的影响:系统综述与网络荟萃分析
该系统综述与网络荟萃分析检索了截至2025年4月21日的多个数据库及FDA网站,纳入151项随机对照试验和17份FDA报告,共58,534名参与者,比较30种抗抑郁药与安慰剂。研究发现抗抑郁药在代谢和血流动力学效应上存在临床显著差异,例如阿戈美拉汀与马普替林之间体重变化差异约4 kg。作者认为治疗指南应更新以反映生理风险差异,但药物选择应个体化。
要点
- 抗抑郁药在体重、心率、血压等心血管代谢参数上的效应存在临床显著差异。
- 帕罗西汀、度洛西汀、去甲文拉法辛和文拉法辛与总胆固醇升高相关,度洛西汀还与血糖升高相关。
- 未发现任何抗抑郁药对QTc、钠、钾、尿素和肌酐产生临床显著影响的强证据。
核心结论
- 有强证据表明抗抑郁药在生理效应上存在显著差异,尤其是心血管代谢参数。
- 治疗指南应更新以反映生理风险差异,但抗抑郁药的选择应基于个体情况,考虑临床表现及患者、照护者和临床医生的偏好。
研究设计与样本
- 系统综述与频率学随机效应网络荟萃分析,检索MEDLINE、EMBASE、PsycINFO、ClinicalTrials.gov和FDA网站,从数据库建库至2025年4月21日。
- 纳入单盲和双盲随机对照试验,比较抗抑郁药与安慰剂在任一精神障碍急性单药治疗中的效果。
- 共纳入151项研究和17份FDA报告,总样本58,534名参与者,比较30种抗抑郁药与安慰剂。
- 中位治疗持续时间8周(IQR 6.0-8.5)。
主要发现
- 阿戈美拉汀与马普替林之间体重变化差异约4 kg。
- 氟伏沙明与去甲替林之间心率变化差异超过21次/分。
- 去甲替林与多塞平之间收缩压差异超过11 mmHg。
- 帕罗西汀、度洛西汀、去甲文拉法辛和文拉法辛与总胆固醇升高相关,度洛西汀还与血糖升高相关,尽管所有药物均降低体重。
- 有强证据表明度洛西汀、去甲文拉法辛和左米那普仑升高AST、ALT和ALP浓度,但变化幅度不被认为具有临床意义。
临床怎么用
- 作者认为治疗指南应更新以反映生理风险差异。
- 作者认为抗抑郁药的选择应基于个体情况,考虑临床表现及患者、照护者和临床医生的偏好。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antidepressants induce physiological alterations; however, the degree to which these occur in treatment with various antidepressants is unclear. We aimed to compare and rank antidepressants based on physiological side-effects by synthesising data from randomised controlled trials (RCTs). METHODS: We searched MEDLINE, EMBASE, PsycINFO, ClinicalTrials.gov, and the US Food and Drug Administration (FDA) website from database inception to April 21, 2025. We included single-blinded and double-blinded RCTs comparing antidepressants and placebo in acute monotherapy of any psychiatric disorder. We did frequentist random-effects network meta-analyses to investigate treatment-induced changes in weight; total cholesterol; glucose; heart rate; systolic and diastolic blood pressure; corrected QT interval (QTc); sodium; potassium; aspartate transferase (AST); alanine transaminase (ALT); alkaline phosphatase (ALP); bilirubin; urea; and creatinine. We did meta-regressions to examine study-level associations between physiological change and age, sex, and baseline weight. We estimated the correlation between depressive symptom severity change and metabolic parameter change. FINDINGS: Of 26 252 citations, 151 studies and 17 FDA reports met inclusion criteria. The overall sample included 58 534 participants, comparing 30 antidepressants with placebo. Median treatment duration was 8 weeks (IQR 6·0-8·5). We observed clinically significant differences between antidepressants in terms of metabolic and haemodynamic effects, including an approximate 4 kg difference in weight-change between agomelatine and maprotiline, over 21 beats-per-minute difference in heart rate change between fluvoxamine and nortriptyline, and over 11 mmHg difference in systolic blood pressure between nortriptyline and doxepin. Paroxetine, duloxetine, desvenlafaxine, and venlafaxine were associated with increases in total cholesterol and, for duloxetine, glucose concentrations, despite all drugs reducing bodyweight. There was strong evidence of duloxetine, desvenlafaxine, and levomilnacipran increasing AST, ALT, and ALP concentrations, although the magnitudes of these alterations were not considered clinically significant. We did not find strong evidence of any antidepressant affecting QTc, or concentrations of sodium, potassium, urea, and creatinine to a clinically significant extent. Higher baseline bodyweight was associated with larger antidepressant-induced increases in systolic blood pressure, ALT, and AST, and higher baseline age was associated with larger antidepressant-induced increases in glucose. We did not observe an association between changes in depressive symptoms and metabolic disturbance. INTERPRETATION: We found strong evidence that antidepressants differ markedly in their physiological effects, particularly for cardiometabolic parameters. Treatment guidelines should be updated to reflect differences in physiological risk, but choice of antidepressant should be made on an individual basis, considering clinical presentation and preferences of patients, carers, and clinicians. FUNDING: National Institute for Health Research, Maudsley Charity, Wellcome Trust, Medical Research Council.
引用
- Pillinger T, Arumuham A, McCutcheon RA, et al. The effects of antidepressants on cardiometabolic and other physiological parameters: a systematic review and network meta-analysis. Lancet. 2025. PMID: 41135546. doi:10.1016/S0140-6736(25)01293-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。